Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.30 |
| ▸ | BLM | P54132 | 2/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370811 | 1.00 | HCAR2 (0.54) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL370884 | 1.00 | HCAR2 (0.54) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL2705194 | 0.91 | HCAR2 (0.39) | HCAR2 | |
| SCHEMBL370810 | 0.91 | HCAR2 (0.39) | HCAR2 | |
| SCHEMBL370883 | 0.91 | HCAR2 (0.39) | HCAR2 | |
| SCHEMBL8019533 | 0.78 | HCAR2 (0.30) | HCAR2 | |
| SCHEMBL656053 | 0.78 | HCAR2 (0.34) | HCAR2 | |
| SCHEMBL656054 | 0.78 | HCAR2 (0.34) | HCAR2 | |
| SCHEMBL11245978 | 0.77 | HCAR2 (0.52) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL17512887 | 0.77 | HCAR2 (0.52) | HCAR2TSHRTP53EGLN1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000710-A1 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS | NITTO DENKO CORPORATION (JP) | 2024-01-04 | — | — | US | claimed |
| EP-3324932-B1 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS | NITTO DENKO CORP (JP) | 2021-03-10 | — | — | EP | claimed |
| US-20190231695-A1 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS | NITTO DENKO CORPORATION (JP) | 2019-08-01 | — | — | US | claimed |
| US-10300018-B2 | Compositions and methods for nanoparticle lyophile forms | NITTO DENKO CORPORATION (JP) | 2019-05-28 | — | — | US | claimed |
| EP-3324932-A1 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS | Nitto Denko Corporation (JP) | 2018-05-30 | — | — | EP | claimed |
| US-20170020819-A1 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS | NITTO DENKO CORPORATION (JP) | 2017-01-26 | — | — | US | claimed |
| WO-2017015552-A1 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS | NITTO DENKO CORPORATION (JP) | 2017-01-26 | — | — | WO | claimed |
| US-6783006-B1 | Container for chemicals | SYNGENTA INVESTMENT CORP. | 2004-08-31 | — | — | US | claimed |
| EP-0746514-B1 | PROCESS FOR THE FABRICATION OF A CONTAINER FOR CHEMICALS | NOVARTIS AG (CH) | 1999-04-14 | — | — | EP | claimed |
| EP-0746514-A1 | CONTAINER FOR CHEMICALS | Novartis AG (CH) | 1996-12-11 | — | — | EP | claimed |
| WO-1995023099-A1 | CONTAINER FOR CHEMICALS | CIBA-GEIGY AG (CH) | 1995-08-31 | — | — | WO | claimed |
| WO-1995019921-A1 | A PACKAGE SYSTEM FOR CHEMICALS | CIBA-GEIGY AG (CH) | 1995-07-27 | — | — | WO | claimed |
| US-5142009-A | Crosslinked blend of fumaric acid diesters | TOMEI SANGYO KABUSHIKI KAISHA (JP) | 1992-08-25 | — | — | US | claimed |
| EP-0046136-B1 | MEMBRANE MODIFIED HYDROGELS, PROCESS FOR THEIR MANUFACTURE AND THEIR USE AS ACTIVE AGENT DISPENSER | CIBA-GEIGY AG (CH) | 1984-05-30 | — | — | EP | claimed |
| EP-0046136-A2 | Membrane modified hydrogels, process for their manufacture and their use as active agent dispenser | CIBA-GEIGY AG (CH) | 1982-02-17 | — | — | EP | claimed |
| US-4304591-A | A HIGH-STRENGTH GEL OF MALEIMIDE-MODIFIED POLYOXYPROPYLENE OR -TETRAMETHYLENE GLYCOL CROSSLINKED BY A WATER-SOLUBLE OLEFIN; SUSTAINED RELEASE | CIBA-GEIGY CORPORATION (US) | 1981-12-08 | — | — | US | claimed |
| US-4277582-A | MEMBRANES AND CARRIERS FOR SUSTAINED RELEASE | CIBA-GEIGY CORPORATION (US) | 1981-07-07 | — | — | US | claimed |
| US-4192827-A | IN A DELAMINATED MATRIX OF A TRANSITITION METAL DICHALCOGENIDE | CIBA-GEIGY CORPORATION (US) | 1980-03-11 | — | — | US | claimed |
| US-4177056-A | CROSSLINKED; SUSTAINED RELEASE | CIBA-GEIGY CORPORATION (US) | 1979-12-04 | — | — | US | claimed |
| US-4136250-A | CROSSLINKED, ADDITION MONOMER OR POLYMER | CIBA-GEIGY CORPORATION (US) | 1979-01-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000710-A1 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS | DDOST, RNASE1, DIS3 | HCAR2 4816/4885TSHR 4228/4885TP53 467/4885 |
| US-20190231695-A1 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS | DDOST, RNASE1, DIS3 | HCAR2 4817/4885TSHR 4352/4885TP53 611/4885 |
| US-20170020819-A1 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS | DDOST, RNASE1, DIS3 | HCAR2 4817/4885TSHR 4352/4885TP53 611/4885 |
| US-10300018-B2 | Compositions and methods for nanoparticle lyophile forms | DDOST, RNASE1, DIS3 | HCAR2 4817/4885TSHR 4352/4885TP53 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.